Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with stereotactic needle biopsy may make biopsy safer.[6-9] Biopsy is recommended for pontine tumors when the diagnosis is uncertain based on imaging findings.
Available CBTN Biospecimens
participants with flash-frozen tissue available
participants with match blood
participants with match parental specimens
participants with cerebral spinal fluid
Available CBTN Pre-clinical Models
genomically characterized cell lines with data available
genomically characterized pdx with data available
Explore the data in these informatics portals
How do I get access to the data?
To access the data please follow these instructions. Need help? Contact us at email@example.com
You can access processed data today here by simply logging in to PedcBioPortal
You can request raw data by completing this form. The review normally takes 1 week. Once approved you can access the raw data by creating cohorts of interest on the Kids First Data Resource Portal and performing analysis on the cloud in Cavatica
Using Whole Genome Bisulfite Sequencing to Identify Novel Therapeutic Targets in DIPG and ATRT
Diffuse intrinsic pontine gliomas (DIPG) and atypical teratoid rhabdoid tumors (ATRT) develop some tumor forms that are particularly resistant to therapies. To better understand these differences, researchers will analyze DIPG and ATRT samples provided by the Children’s Brain Tumor Network.
Elucidate Potential Therapeutic Targets in H3.3G34 Mutant pHGG cells
Histone mutations have been identified as drivers of some pediatric brain cancers. Researchers seek to understand the role of such mutations in the development of pediatric high grade gliomas through analysis of rare specimens provided by the Children’s Brain Tumor Network.
Regional Response to ONC201 in Pediatric High-Grade Glioma
New targeted therapies are needed to address pediatric high grade gliomas with H3K27M mutations. The Children’s Brain Tumor Network will provide researchers with pHGG cell lines and data to pursue the development of therapeutics.